EUVIMEDEUVIMED entdecken
Crossref

Malignant Ovarian Tumors: Challenges and Advances in Modern Oncology

Parveen Shahida Akhtar

Journal of Ahsania Mission of Cancer & General Hospital · 01.07.2026 · 2 (2) · 51

DOI: 10.65292/jamcgh.2026.v2e2.01 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ahsania Mission of Cancer & General Hospital, online erschienen am 01.07.2026. Verfasst von Parveen Shahida Akhtar. Die Arbeit nennt 3 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant ovarian tumors remain a formidable challenge in gynecologic oncology. Despite remarkable progress in surgery, chemotherapy, molecular diagnostics, and targeted treatment, ovarian cancer continues to be associated with substantial mortality, largely because many women present with advanced disease. The nonspecific nature of symptoms—including abdominal bloating, dyspepsia, early satiety, pelvic discomfort, altered bowel habits, and urinary symptoms—can result in repeated treatment for benign gastrointestinal or urinary disorders before the underlying malignancy is recognized. The modern approach to ovarian cancer has changed considerably. Ovarian carcinoma is no longer regarded as a single disease; histological and molecular subtypes have distinct biological behavior and therapeutic vulnerabilities. High-grade serous carcinoma constitutes the major histopathological type of advanced epithelial ovarian cancer, while endometrioid, clear-cell, and mucinous carcinomas represent biologically different diseases. Consequently, accurate histopathological diagnosis and molecular characterization are fundamental to contemporary management. Surgery remains a corner stone of treatment. For appropriately selected patients with advanced disease, the objective of cytoreductive surgery should be complete macroscopic resection. However, primary surgery is not suitable for every patient. Neoadjuvant platinum-based chemotherapy followed by interval cytoreductive surgery provides an established alternative when complete primary cytoreduction is unlikely or surgical morbidity is excessive. Such decisions should be made within experienced multidisciplinary teams. Current international recommendations increasingly emphasize specialized ovarian cancer surgery and multidisciplinary decision-making. The modern understanding of ovarian cancer has changed fundamentally. Rather than considering ovarian carcinoma a single disease, contemporary classification recognizes biologically and clinically distinct entities. High-grade serous carcinoma (HGSC) accounts for the majority of advanced epithelial ovarian cancers and is characterized by almost universal TP53 abnormalities, frequent homologous recombination deficiency (HRD), and, in a substantial proportion of cases, germline or somatic BRCA1/2 alterations. Endometrioid, clear-cell, and mucinous carcinomas possess different molecular landscapes and therapeutic vulnerabilities. This histologic and molecular heterogeneity makes accurate pathology and molecular characterization essential components of modern management. Platinum-based chemotherapy remains the backbone of systemic treatment, but the era of chemotherapy alone is rapidly disappearing. Germline and somatic BRCA1/2 testing, together with assessment of homologous recombination deficiency (HRD),has become increasing important in treatment selection. The introduction of PARP inhibitors—including olaparib, niraparib, and rucaparib—has transformed maintenance treatment, particularly for patients with BRCA-mutated or HRD-positive tumors1. These advances demonstrate the clinical value of moving from a histology-driven to a biomarker-driven treatment strategy. The treatment landscape is continuing to expand beyond PARP inhibition. Antiangiogenic therapy with bevacizumab remains relevant in selected patients, while molecularly directed approaches are increasingly important in recurrent disease. The 2026 ESMO Express Update incorporates mirvetuximab soravtansine for selected patients with recurrent, high-FRα ovarian cancer, illustrating the movement toward treatment based on tumor biology rather than stageand histology alone2. Folatereceptoralpha (FRα) has emerged as an important therapeutic target, exemplified by the development of mirvetuximab soravtansine for FRα-positive ovarian cancer. The patients with biomarkers such as MSI-high/dMMR may derive meaningful benefit. Recurrent ovarian cancer represents another major clinical challenge. Treatment should no longer be determined solely by the traditional concept of platinum sensitivity. Histopathological type, BRCA/HRD status, previous treatment and maintenance exposure, treatment-free interval, residual toxicity, performance status, possibility of secondary cytoreduction, and patient preference should all influence therapeutic decisions. Pan-Asian adaptations of ESMO guidance emphasize these individualized factors, which are particularly relevant in resource-diversesettings3.

Zitieren

APA

Akhtar, P. S. (2026). Malignant Ovarian Tumors: Challenges and Advances in Modern Oncology. Journal of Ahsania Mission of Cancer & General Hospital, 2(2), 51. https://doi.org/10.65292/jamcgh.2026.v2e2.01

Vancouver

Akhtar PS. Malignant Ovarian Tumors: Challenges and Advances in Modern Oncology. Journal of Ahsania Mission of Cancer & General Hospital. 2026;2(2):51. doi:10.65292/jamcgh.2026.v2e2.01

BibTeX
@article{Akhtar2026,
  author = {Akhtar, Parveen Shahida},
  title = {Malignant Ovarian Tumors: Challenges and Advances in Modern Oncology},
  journal = {Journal of Ahsania Mission of Cancer & General Hospital},
  year = {2026},
  volume = {2},
  number = {2},
  pages = {51},
  doi = {10.65292/jamcgh.2026.v2e2.01}
}
Kostenlos starten →